Chief Executive Officer
Mr. Dowling was appointed as Chief Executive Officer of the Company in May 2018. Prior to his appointment as CEO, Mr. Dowling held the position of CFO with the Company since 2014. Prior to 2014, Mr. Dowling held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company focused on drug formulation and delivery from 2005 to 2013 where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific. Mr. Dowling also served as a Managing Director at Citigroup, a global financial services firm, and earlier in his career served various operating, finance and accounting roles in both public accounting and in the banking industry. Mr. Dowling graduated from University of California, Los Angeles in Economics and is a certified public accountant.
Chief Financial Officer
Mr. Grasser has more than 20 years of experience and an extensive background in accounting, finance, financial reporting and operations. Prior to his role at CV Sciences, Mr. Grasser was Controller at Ballast Point Brewing, a subsidiary of Constellation Brands, Inc. from 2015 to 2018. Prior to his role at Ballast Point, Mr. Grasser held senior finance positions with Sequenom, Inc. from 2014 to 2015 and Peregrine Semiconductor Corporation from 2010 to 2014. Mr. Grasser began his career at KPMG LLP providing audit and IT advisory services, advancing to senior audit manager. Mr. Grasser has an MBA from the Keller Graduate School of Management, a BA from University of Regensburg and is a Certified Public Accountant.
Vice President, Human Nutrition
Mr. Tomc is a recognized authority on dietary supplements, with twenty years of experience in the nutritional health industry. Formerly the Vice President of North American Herb and Spice, where he served for 10 years, in addition to his service as Global Educator for omega-3 market leader, Nordic Naturals, Mr. Tomc is known for his extensive print interviews and contributions to noted books on integrative medicine, as well as his 4000 radio appearances. A renowned educator, Mr.Tomc recognizes CBD and its multiple mechanisms of action to support human health, and envisions a new category of dietary supplements derived from agricultural hemp.
Dr. Douglas MacKay, N.D.
Senior Vice President of Scientific and Regulatory Affairs
Dr. MacKay serves on the advisory board for the American Botanical Council, the NSF International Joint Committee on Dietary Supplements, and the NIST/NIH Dietary Supplement Laboratory Quality Assurance Program. He is a licensed naturopathic doctor and previously was owner and practitioner in a New Hampshire-based integrative medical practice. Additionally, Dr. MacKay is on the editorial board of three peer-reviewed publications: the official publication of the American Association of Naturopathic Physicians, Natural Medicine Journal, Integrative Medicine—a Clinician’s Journal, and Current Topics in Nutraceutical Research. Dr. MacKay is also Chair of the Steering Committee for the SIDI Work Group.
Dr. MacKay holds a bachelor’s in Marine Biology from the University of California, Santa Cruz and his N.D. from the National College of Natural Medicine in Portland, Oregon.
Tim Hitchman, PhD
Director of Operations
Most recently, from late 2018, Dr. Hitchman served as Chief Technology Officer at Tradewinds Holding LLC, a start-up cannabis oils production company. In this role, he led development and scaling of an innovative “warm-ethanol” extraction and production process, and he was responsible for site operations.
Earlier in 2018, Dr. Hitchman was engaged as a Project Director for the DSM Nutritional Products Group, where he drove a change in business focus and operations to develop and deliver consumer-led product concepts. Prior to 2018, Dr. Hitchman served in a variety of roles at DSM, most recently as Innovation Director Growth Platforms, where he led development of numerous strategic products targeting new growth opportunities, including launch of two new enzyme products.
Prior to DSM, Dr. Hitchman served in a variety of roles at Verenium Corporation (formerly Diversa Corporation) from 2001-2012, where he built the Oils & Fats Enzymes business from launch of the first product in 2008, with responsibility for sales & marketing, as well as oversight of production development. Before taking on this commercial role, he had leadership roles in the Verenium R&D organization managing strategic partnerships with Bunge and Givaudan and leading development of several products from concept to commercialization.
Dr. Hitchman earned a BA in Chemistry from Oxford University and a PhD in Bio-Organic Chemistry from Bristol University, both in the UK.